Core Insights - Bloomin' Brands (BLMN) reported quarterly earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, but down from $0.70 per share a year ago, indicating a 15.71% year-over-year decline [1] - The company achieved revenues of $1.05 billion for the quarter, surpassing the Zacks Consensus Estimate by 1.32%, but down from $1.2 billion year-over-year, reflecting a 12.5% decrease [2] - Bloomin' Brands has underperformed the market, with shares down approximately 35.1% year-to-date compared to the S&P 500's decline of 4.7% [3] Earnings Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The earnings surprise for the latest quarter was 3.51%, with no surprise in the previous quarter where actual earnings matched expectations [1][2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.36 on revenues of $985.29 million, and for the current fiscal year, it is $1.28 on revenues of $3.91 billion [7] - The estimate revisions trend for Bloomin' Brands is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Retail - Restaurants industry, to which Bloomin' Brands belongs, is currently in the bottom 20% of the Zacks industry rankings, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Bloomin' Brands' stock performance [5]

Geron (GERN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this drugmaker would post a loss of $0.02 per share when it actually produced a loss of $0.04, delivering a surprise of -100%. Empirical research shows a strong correlation between near-term ...

Verisk Analytics (VRSK) came out with quarterly earnings of $1.73 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.59%. A quarter ago, it was expected that this insurance data provider would post earnings of $1.60 per share when it actually produced earnings of $1.61, delivering a surprise of 0.63%. Over the last four quart ...

Middleby (MIDD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.22%. A quarter ago, it was expected that this food preparation equipment company would post earnings of $2.50 per share when it actually produced earnings of $2.88, delivering a surprise of 15.20%.Over the last four qua ...

Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -180%. A quarter ago, it was expected that this drugmaker would post earnings of $0.10 per share when it actually produced earnings of $0.02, delivering a surprise of -80%.Over the last four quarters, the company ...

Company Performance - C4 Therapeutics reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.41 per share a year ago, representing an earnings surprise of 22.92% [1] - The company posted revenues of $7.24 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 103.03%, compared to revenues of $3.04 million in the same quarter last year [2] - Over the last four quarters, C4 Therapeutics has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - C4 Therapeutics shares have declined approximately 60.8% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $7.25 million, and for the current fiscal year, it is -$1.74 on revenues of $22.72 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact C4 Therapeutics' stock performance [5]

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.59%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.50 per share when it actually produced earnings of $2.66, delivering a surprise ...

Core Viewpoint - Hain Celestial reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share, representing a -41.67% earnings surprise [1][2] Financial Performance - The company posted revenues of $390.35 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.10%, compared to $438.36 million in the same quarter last year [2] - Over the last four quarters, Hain Celestial has surpassed consensus EPS estimates only once [2] Stock Performance - Hain Celestial shares have declined approximately 55% since the beginning of the year, while the S&P 500 has decreased by -4.7% [3] - The current Zacks Rank for Hain Celestial is 4 (Sell), indicating expected underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $410.8 million, and for the current fiscal year, it is $0.33 on revenues of $1.63 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6] Industry Context - The Food - Miscellaneous industry, to which Hain Celestial belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Forge Global Holdings, Inc. (FRGE) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $1.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.73%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.20, delivering a surprise of 11.11%.Over the last four quarters, the company h ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. What's Next for Apellis Pharmaceuticals? While Apellis Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measu ...